You are here

  • Home
  • Archive
  • Volume 19, Issue 4
  • Omalizumab decreases exacerbations and allows a step down in daily inhaled corticosteroid dose in adults and children with moderate-to-severe asthma

Article Text

Article menu
Download PDFPDF
Therapeutics
Systematic review and meta-analysis
Omalizumab decreases exacerbations and allows a step down in daily inhaled corticosteroid dose in adults and children with moderate-to-severe asthma

https://doi.org/10.1136/eb-2014-101759

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Correction notice This article has been corrected since it was published Online First. The word ‘exacerbation’ has been corrected to ‘exacerbations’ in the article title.

    • Competing interests NCT has participated in advisory boards and/or received consultancy fees from Asmacure, Chiesi and Respivert. He has received lecture fees from Boston Scientific, Chiesi, GlaxoSmithKline and Novartis, and industry-sponsored grant funding to the University of Glasgow from AstraZeneca, Boston Scientific, Genentech, GlaxoSmithKline, Novartis, Pfizer and Synairgen for participating in clinical trials.